ImageneBio (IMA)
NASDAQ:IMA
Top Page
ImageneBio
(NASDAQ:IMA)
Select Model
Select Model
Rating:41Neutral
Price Target:
$5.00
▲(5.26% Upside)
Action:ReiteratedDate:03/28/26
The score is driven primarily by weak financial performance (declining revenue to $0, widening losses, and ongoing cash burn), despite low leverage. Technicals add further pressure with a clear downtrend and negative MACD, though the stock is oversold. Valuation provides little support due to negative earnings and no dividend yield.
Positive Factors
Modest leverage
Low debt-to-equity reduces immediate financial distress risk and preserves flexibility for a pre-commercial biotech. With limited leverage, the company can prioritize R&D and strategic options without high interest burdens, improving resilience during prolonged development timelines.
Negative Factors
Revenue declined to zero
Falling to zero reported revenue indicates the company is fully pre-commercial or lacks recurring licensing income, increasing reliance on external financing. Without product cash flows, long-term sustainability depends on successful trials or partnerships, intensifying execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Modest leverage
Low debt-to-equity reduces immediate financial distress risk and preserves flexibility for a pre-commercial biotech. With limited leverage, the company can prioritize R&D and strategic options without high interest burdens, improving resilience during prolonged development timelines.
Read all positive factors
ImageneBio (IMA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$51.12M
Dividend YieldN/A
Average Volume (3M)69.52K
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue Growth-100.00%
EPS Growth45.48%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,654,281
10 Day Avg. Volume58,561
30 Day Avg. Volume69,515
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.25
Price to Sales (P/S)42.01
P/FCF Ratio-0.70
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.05
Enterprise Value/Ebitda-0.52
Forecast
1Y Price Target
$2.00Price Target Upside-57.89% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ImageneBio Business Overview & Revenue Model
Company Description
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis...
How the Company Makes Money
Public, verifiable details about ImageneBio’s specific revenue model and revenue streams (e.g., product sales, named licensing/royalty arrangements, collaboration revenue, or service revenue) are not available in the information provided, and I do...
ImageneBio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
26
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 800.00K | 3.50M | 9.16M | 15.62M | 30.98M |
| Gross Profit | -233.00K | 3.50M | 8.14M | -48.70M | -16.12M |
| EBITDA | -47.42M | -35.47M | -74.40M | -70.15M | -33.59M |
| Net Income | -45.35M | -36.57M | -68.17M | -68.77M | -34.12M |
Balance Sheet | |||||
| Total Assets | 152.98M | 141.51M | 192.09M | 172.26M | 247.88M |
| Cash, Cash Equivalents and Short-Term Investments | 75.78M | 124.39M | 175.47M | 156.95M | 232.22M |
| Total Debt | 9.99M | 7.52M | 10.74M | 5.69M | 6.99M |
| Total Liabilities | 19.84M | 15.58M | 22.34M | 25.29M | 40.00M |
| Stockholders Equity | 133.14M | 125.93M | 169.76M | 146.97M | 207.88M |
Cash Flow | |||||
| Free Cash Flow | -47.84M | -46.00M | -80.16M | -75.54M | -62.01M |
| Operating Cash Flow | -47.84M | -46.00M | -79.74M | -74.11M | -60.25M |
| Investing Cash Flow | -5.81M | -34.90M | 64.14M | -99.28M | -1.76M |
| Financing Cash Flow | 135.47M | 0.00 | 75.98M | 1.09M | 131.74M |
ImageneBio Technical Analysis
Negative
4.75
Price Trends
6.27
Negative
6.54
Negative
9.26
Negative
Market Momentum
-0.42
Positive
29.63
Positive
43.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMA, the sentiment is Negative. The current price of 4.75 is below the 20-day moving average (MA) of 5.49, below the 50-day MA of 6.27, and below the 200-day MA of 9.26, indicating a bearish trend. The MACD of -0.42 indicates Positive momentum. The RSI at 29.63 is Positive, neither overbought nor oversold. The STOCH value of 43.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMA.
ImageneBio Risk Analysis
ImageneBio disclosed 73 risk factors in its most recent earnings report. ImageneBio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ImageneBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $249.40M | -0.60 | -118.95% | ― | ― | 31.98% | |
53 Neutral | $189.54M | -4.05 | -86.91% | ― | -87.59% | 11.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $83.74M | -90.96 | -57.20% | ― | 9.06% | ― | |
49 Neutral | $84.20M | -0.79 | -69.56% | ― | ― | 14.19% | |
47 Neutral | $155.25M | -8.55 | -1197.81% | ― | ― | 30.16% | |
41 Neutral | $51.12M | -0.74 | -33.05% | ― | -100.00% | 45.48% |
* Healthcare Sector Average
IMA
ImageneBio
4.57
-8.63
-65.38%
IMUX
Immunic
1.19
0.27
28.79%
CSBR
Champions Oncology
6.03
-2.43
-28.72%
PLRX
Pliant Therapeutics
1.36
0.05
3.82%
ALXO
ALX Oncology Holdings
1.90
1.38
264.42%
ADAG
Adagene
4.00
2.60
185.71%
ImageneBio Corporate Events
Executive/Board Changes
ImageneBio Announces Leadership Transition in Finance Organization
Neutral
Mar 17, 2026
On March 12, 2026, ImageneBio, Inc. agreed to a mutual separation with Erin Butler, its Senior Vice President, Finance Administration and Principal Accounting Officer, effective March 20, 2026, with Butler expected to receive severance benefits u...
Executive/Board Changes
ImageneBio announces immediate resignation of board director
Neutral
Feb 17, 2026
On February 12, 2026, ImageneBio, Inc. announced that Steven Hui Wang resigned from its Board of Directors, effective immediately. The company stated that Wang’s departure did not arise from any disagreement regarding ImageneBio’s oper...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.